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Interactions of drug molecules with lipid membranes play crucial role in their accessibility
of cellular targets and can be an important predictor of their therapeutic and safety
profiles. Very little is known about spatial localization of various drugs in the lipid bilayers,
their active form (ionization state) or translocation rates and therefore potency to bind
to different sites in membrane proteins. All-atom molecular simulations may help to
map drug partitioning kinetics and thermodynamics, thus providing in-depth assessment
of drug lipophilicity. As a proof of principle, we evaluated extensively lipid membrane
partitioning of d-sotalol, well-known blocker of a cardiac potassium channel Kv11.1
encoded by the hERG gene, with reported substantial proclivity for arrhythmogenesis.
We developed the positively charged (cationic) and neutral d-sotalol models, compatible
with the biomolecular CHARMM force field, and subjected them to all-atom molecular
dynamics (MD) simulations of drug partitioning through hydrated lipid membranes,
aiming to elucidate thermodynamics and kinetics of their translocation and thus putative
propensities for hydrophobic and aqueous hERG access. We found that only a neutral
form of d-sotalol accumulates in the membrane interior and can move across the bilayer
within millisecond time scale, and can be relevant to a lipophilic channel access. The
computed water-membrane partitioning coefficient for this form is in good agreement
with experiment. There is a large energetic barrier for a cationic form of the drug,
dominant in water, to cross the membrane, resulting in slow membrane translocation
kinetics. However, this form of the drug can be important for an aqueous access pathway
through the intracellular gate of hERG. This route will likely occur after a neutral form
of a drug crosses the membrane and subsequently re-protonates. Our study serves to
demonstrate a first step toward a framework for multi-scale in silico safety pharmacology,
and identifies some of the challenges that lie therein.
Keywords: hERG, longQT syndrome, cardiotoxicity, CHARMM force field, molecular dynamics, umbrella sampling,
lipophilicity, water-membrane partitioning
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INTRODUCTION
The continuing failure to accurately predict the risk of drug
toxicity is the primary reason for drug candidates being
abandoned or approved drugs being removed from the market
(Chi, 2013), illustrating the critical need for a more rational
approach to drug development. One example of such a need
is the longstanding failure of drug-based treatment of cardiac
arrhythmias. The SWORD clinical trial (Waldo et al., 1996)
famously showed that the antiarrhythmic drug d-sotalol, which
we focus on in this work, actually increased mortality and risk
of sudden cardiac death in patients, leading to its removal from
the marketplace. Similarly, the gastrokinetic agent cisapride has
been removed from the market in many countries due to its
arrhythmogenic potential (Quigley, 2011), and a number of such
cases for drugs and drug candidates with diverse pharmacological
action has been growing over the years. Each year, over 360,000
people die in the US die from cardiac arrhythmias that are
often drug-induced, demonstrating that the pharmacological
assessment of cardiotoxicity still remains significantly hindered
(Benjamin et al., 2017). The proposed Comprehensive in vitro
Proarrhythmia Assay (CiPA) initiative is intended to address
this shortcoming by improving predictions of pro-arrhythmic
drug proclivities through the combination of in vitro assays
on several cardiac ion channels and multi-scale modeling and
simulation (Colatsky et al., 2016; Fermini et al., 2016). Atomistic
MD simulations have the potential to serve as part of such in silico
screen (Clancy et al., 2016) for the development of cardiac-safe
medicines, and can be used to identify molecular determinants of
acquired arrhythmogenesis.
On the molecular level, drug-induced arrhythmogenesis is
typically associated with the binding of drugs to cardiac ion
channels, membrane proteins responsible for the propagation
of electrical signal in cardiomyocytes. It is known that multiple
environmental factors, including drug blockade, can modulate
the gating and permeation of many ion channels. More
specifically, experimental studies aimed at understanding ion
channel blockade by drugs often focus on mapping binding
sites at or around the intra-cellular cavity of the ion channel.
This assumes, either explicitly or implicitly, that a drug (often
weakly cationic) is able to diffuse from the intra-cellular space
and physically occlude ion permeation. Such a mechanism is
supported, for example, by the role of two intra-cavity residues
(F656 and Y652) in the drug-induced current block of the voltage
gated potassium channel KV11.1 (also known as hERG), which
Abbreviations: aLQTS, acquired Long QT syndrome; CGENFF, CHARMM
generalized force field; CHARMM, Chemistry at Harvard Molecular
Mechanics; CiPA, comprehensive in vitro pro-arrhythmic assay; CisC, cationic
cisapride; COM, center of mass; Cryo-EM, cryo-electron microscopy; DMPC,
dimyristoylphosphatidylcholine; ECG, electro-cardiogram; GPU, Graphics
Processing Unit; hERG, human Ether-à-go-go-Related Gene; Kv, voltage gated
potassium channel; LQTS, Long QT syndrome; MD, molecular dynamics;
MM, molecular mechanics; MoxZ, zwitterionic moxifloxacin; PBC, periodic
boundary conditions; PMF, potential of mean force; POPC, 1-palmitoyl-2-
oleoyl-phosphatidylcholine; POPS, 1-palmitoyl-2-oleoyl-phosphatidylserine; QM,
quantum mechanics; SotA, anionic d-sotalol; SotC, cationic d-sotalol; SotN,
neutral d-sotalol; SotZ, zwitterionic d-sotalol; US, umbrella sampling; VSD,
voltage sensing domain; WHAM, weighted histogram analysis method.
is considered a major drug anti-target due to its promiscuous
binding of many drug-like molecules (Vandenberg et al., 2012).
Many of the common ion channel blockers are weak bases
with a pKa of ∼7.8–8.5. Thus, at a physiological pH of 7.4, up
to ∼7–28% of drug molecules remain uncharged, and therefore
potentially capable of interacting with the channel by traversing
a lipophilic pathway in the plasma membrane toward a binding
site, either on the lipid-facing exterior of the channel or within
the channel pore via passage through lipid-facing fenestrations.
A possible lipophilic access route has been established for
ivabradine blockade of hERG in a recent study that implicated
a lipid-facing residue (M651) as critical for drug-induced
blockade (Lees-Miller et al., 2015). This finding was further
substantiated by the recent publication of Cryo-EM structures
of hERG (putatively open), and related EAG (putatively closed)
channels, suggesting that F656 and M651 can be exposed to
lipids in either channel state (Whicher and MacKinnon, 2016;
Wang and MacKinnon, 2017). Furthermore, hERG block by the
endogenous components of cardiac membranes has also been
well-established, with various lipophilic molecules including
hormones (Yang et al., 2017), ceramides (Ganapathi et al.,
2010; Sordillo et al., 2015), sphingosine-1-phosphate (Sordillo
et al., 2015), and polyunsaturated fatty acids (Guizy et al.,
2005; Moreno et al., 2012) blocking hERG but without obvious
intra-cellular access to the intra-cavity site. Therefore, mapping
the lipophilic pathways for common ion channel blockers and
understanding the chemistry of drug-lipid interactions remains
an unmet pharmacological challenge.
The complexity in understanding the lipophilic access
pathways of many blockers arises from their chemical structure.
Most drug molecules can coexist in multiple ionization states
with different membrane permeabilities or localization on the
bilayer surface and consequent access to binding sites in hERG.
Hence, significant challenges exist in developing a framework
for atomic-scale in silico screening and predictive pharmacology.
One example is the lack of robust topologies and parameters
defined for most drugs in popular MD force fields, necessitating
their de novo development. This task requires computationally
expensive calculations of quantum mechanical (QM) optimized
molecular geometries and atomic charge distributions, and
the time-consuming process of fitting molecular mechanical
(MM) parameters to the optimal computed QM data. Here we
have developed CHARMM generalized force field (CGENFF)
(Vanommeslaeghe et al., 2010) parameters for the hERG blocker
d-sotalol, which has high cardiotoxic risk (Colatsky et al.,
2016) for the ventricular tachycardia characterized by Torsades
de Pointes (TdP) arrhythmias (Waldo et al., 1996; Yap and
Camm, 2003). Preliminary parameters for the intermediate-
TdP risk compound cisapride (Colatsky et al., 2016), and
low-risk compound moxifloxacin (Haverkamp et al., 2012)
were developed for the purpose of comparing their membrane
affinities, and will be briefly discussed as well.
Computing the free energy cost required for drugs to partition
from bulk solution across the cell membrane represents a critical
test for drug model viability used in MD simulations. This
is because the membrane permeability of a drug not only
determines its bioavailability, but is also linked to its medically
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relevant concentration, and pathway to its target. Many drugs
are delivered to their targets via a lipophilic pathway, and
drug permeation across lipid membranes is crucial for their
absorption by tissue, metabolism, extraction from the body,
and toxicity (ADME-Tox) (Yu and Adedoyin, 2003). This is
especially relevant for predicting propensity for off-target effects
of a drug, which is necessarily linked to its tissue permeability.
Empirically derived ADME-Tox drug profiles, however, are
inherently limited, lacking transferability to different drug
classes, and providing no information regarding the structural
determinants of membrane-drug distribution or kinetics (Swift
and Amaro, 2013). Obtaining these measurements through MD
simulation represents a final major challenge: namely, obtaining
sufficient sampling of the configurational space in a modeled
system to calculate accurate thermodynamic quantities of interest.
Ideally, unbiased all-atom MD simulations of drug permeation
across large, explicit lipid membranes would provide the most
accurate kinetic and thermodynamic profiles for membrane-
drug interactions (Swift and Amaro, 2013), however the
sampling (or simulation time) mandated by such an exhaustive
approach makes it computationally prohibitive. Fortunately,
more computationally tractable techniques for enhanced
sampling exist that allow for the robust calculation of membrane
distribution coefficients and permeability measurements of an
isolated drug across a small membrane patch. We have employed
one such technique, umbrella sampling (US) (Torrie and Valleau,
1977), in this report in order to compute the free energies and
diffusion coefficients required for drugs to pass through the cell
membrane. Similar approaches have been used for various drug
molecules in a number of other studies (Carpenter et al., 2014;
Di Meo et al., 2016; Bennion et al., 2017), including previous
works by our groups (Boiteux et al., 2014; Yang et al., 2016). The
approaches and data presented here serve as preliminary steps in
overcoming the many challenges that arise in the messy task of
atomistic in silico predictive cardiovascular pharmacology.
MATERIALS AND METHODS
Drug Force Field Parameterization
We obtained starting molecular structures from either PubChem
(Kim et al., 2016) (CID 5253 for d-sotalol) or the ZINC
(Irwin and Shoichet, 2005) (3775140 for cisapride, 3826253
for moxifloxacin) databases, and used them to generate initial
guesses for partial atomic charges and other force field
parameters (i.e., bond lengths, bond angles, dihedral angles)
using CGENFF program, version 1.0 (Vanommeslaeghe and
MacKerell, 2012; Vanommeslaeghe et al., 2012).
Initial topology and parameters for SotC and SotN, were
subsequently validated and optimized using QM target data
following the suggested CGENFF force field methodology
(Vanommeslaeghe et al., 2010). High-quality parameters not
already present in CGENFF are assigned from existing
parameters based on chemical analogy, with poor chemical
analogy corresponding to a high penalty score for use in MD
simulation (Vanommeslaeghe et al., 2012). Our optimizations
focused on such high-penalty, poorly analogous parameters
generated by the CGENFF program. Quantum mechanical
(QM) target data for parameter optimization were obtained
utilizing Møller–Plesset (MP2) and Hartree-Fock (HF) electronic
structure methods and the 6–31(d) basis set using the Gaussian
09 program (Frisch et al., 2009).
MP2/6-31G(d) molecular dipole magnitude and orientation
as well as scaled HF/6-31G(d) interaction energies with
water were used for partial atomic charge optimization
for compatibility with the CHARMM atomistic biomolecular
force fields (MacKerell, 2004). The gas-phase MP2/6-31G(d)
dipole, along with HF/6-31G(d) interaction energies, should
be overestimated by CHARMM (by ∼16% for the latter) in
order to account for polarization in aqueous media (MacKerell,
2004; Vanommeslaeghe et al., 2010). Internal bond and angle
parameters were validated or modified based on comparison of
MP2/6-31G(d) and CHARMM optimized geometries and scaled
vibrational frequencies. For bond lengths and angles, respective
differences within 0.01 Å and 1◦ between QM and CHARMM
values were sought. Dihedral angle parameters were optimized
to reproduce MP2/6-31G(d) potential energy scans for rotation
around a particular bond.We used the Force Field Toolkit plugin
(fftk) (Mayne et al., 2013) for the Visual Molecular Dynamics
program (VMD) (Humphrey et al., 1996) in order to generate
files for QM reference calculations and to perform parameter
optimizations. We were able to achieve substantial improvement
over the initial CGENFF generated parameters (highlighted
in Figure 3C for a selected dihedral angle energy profile),
with markedly better agreement between CHARMM and QM
geometries, vibrational frequencies, and interactions with water.
Final topology and parameters for SotC and SotN are provided
in the Supplementary Information. Optimized parameters for
charged cisapride and zwitterionic moxifloxacin, obtained using
the same methodology, will be subsequently published after
additional validation and any necessary improvement.
Drug Membrane Partitioning: Molecular
Systems
Partitioning of charged (SotC) and neutral d-sotalol (SotN),
charged cisapride (CisC), and a zwitterionic form ofmoxifloxacin
(MoxZ) were assessed using CHARMM (Brooks et al., 1983,
2009) and NAMD (Phillips et al., 2005) programs. CHARMM-
GUI tool (Jo et al., 2008) was used in order to build the
simulation systems, which consisted of 128 1-palmitoyl-
2-oleoylphosphatidylcholine (POPC) lipids, ∼7,000 water
molecules, 21 or 22 K+ and 22 Cl− ions to ensure 0.15M
electrolyte concentration and overall electrical neutrality, and
one drug molecule, totaling∼38,250 atoms.
A separate set of simulations that investigated membrane
composition was equilibrated with NAMD and run on Anton
2 supercomputer (Shaw et al., 2014). In these simulations lipid
membranes were composed of either pure POPC or a mixture of
85% POPC and 15% of 1-palmitoyl-2-oleoylphosphatidylserine
(POPS) lipids. These systems were larger and contained
∼103,000 atoms with 256 lipids, 15 SotC or 16 SotN molecules,
∼22,800 water molecules, 50–88 K+ and 50–65 Cl− ions.
CHARMMbiomolecular, and compatible CGENFF forcefields
were used throughout all simulations. In particular, C36 lipid
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(Klauda et al., 2010) and standard CHARMM ion parameters
(Beglov and Roux, 1994), newly developed CGENFF drug
parameters (see above) along with the TIP3P water model
(Jorgensen et al., 1983) were utilized.
Drug Membrane Partitioning: Molecular
Dynamics Simulations
CHARMM simulations of SotC, SotN, CisC, and MoxZ, and
NAMD simulations of SotC and SotN in a hydrated 128 lipid
POPC membrane were carried out in NPT ensemble with
1 atm of pressure maintained by Langevin piston barostat
(Feller et al., 1995) and 310K temperature controlled by Nosé-
Hoover thermostat (Nosé, 1984; Hoover, 1985). Tetragonal cells
with periodic boundary conditions (PBC) were used in all the
simulations, with P21 space group (Dolan et al., 2002) utilized
in CHARMM runs. SHAKE algorithm (Ryckaert et al., 1977) was
employed to fix the bonds to all hydrogen atoms, allowing a time
step of 2 fs for all our simulations. Electrostatic interactions were
computed via Particle Mesh Ewald (Darden et al., 1993), with a
mesh grid of 1 Å.
For partitioning calculations of each drug we used the
US method (Torrie and Valleau, 1977) with 81 independent
simulation windows, placing the center of mass (COM) of the
drug in 1 Å intervals from −40 Å to 40 Å with respect to COM
of the membrane. The COM of the drug was restrained along
the z axis with a force constant of 2.5 kcal/mol/Å2 to provide
sufficient sampling with an additional 5 kcal/mol/Å2 cylindrical
constraint applied to prevent the drift of the molecule in the xy
plane (Li et al., 2008). Free energy or potential of mean force
(PMF) profiles was computed using weighted histogram analysis
method (WHAM) (Kumar et al., 1992).
SotC and SotN simulations ran for 15 ns with NAMD and
10 ns with CHARMM per window. To improve sampling, for
NAMD runs we used additional US windows from −20 Å to 20
Å, whereas 7 central windows (i.e., for |z| ≤ 3 Å) were used for
CHARMMSotC simulations, all running for the same simulation
time as the original runs (see Supplementary text). Based on
solvation analysis of SotC and SotN (Figure S5), we discarded
the first 4 ns to account for equilibration. For consistency, similar
procedure was followed for CHARMM simulations of CisC and
MoxZ, both of which ran 10 ns/window plus additional 10 ns for
the 5 central windows (|z|≤2 Å) of CisC.
Unbiased MD simulations were run for larger membrane
systems with several SotC or SotN molecules. First, systems
were equilibrated for 50 ns using NAMD and the simulation
parametersmentioned above. Then, production simulations were
run for 500 or 1000 ns (for SotN system with POPC/POPS mixed
membrane) using Anton 2 software (Shaw et al., 2014) version
1.31.0. These simulations were carried out using tetragonal PBC
in the NPT ensemble at 310K, a 2 fs time step with non-bonded
long range interactions computed every 6 fs using the RESPA
multiple time step algorithm (Tuckerman et al., 1992). The
multi-integrator (multigrator) algorithm (Lippert et al., 2013)
was used for temperature and semi-isotropic pressure coupling,
whereas a novel u-series method (Shaw et al., 2014) was used for
handling long-range electrostatic interactions. An electric field
in the z direction was applied, gradually increasing from 0 to
160mV during the first 100 ns of the simulation. A long-range
Lennard-Jones (LJ) correction (beyond cutoff) was not used as
was suggested for C36 lipid force field (Klauda et al., 2010).
Drug Membrane Partitioning: Simulation
Analyses
Solvation numbers were computed as number of oxygen atoms
of water, lipid phosphate or ester functional groups within 4.25 Å
of drug non-hydrogen atoms, with this distance cutoff obtained
from an analysis of corresponding radial distribution functions
(see Figure S6). Drug orientation was computed based on a polar
angle θ between z axis corresponding to a bilayer normal and
drug N1...S vector, which is almost anti-parallel to its dipole
orientation (see Figure 3). Average angles were computed as:
< θN1...S >= atan2(< sinθ >,< cosθ >) (1)
whereas corresponding order parameters were computed as
(Vorobyov et al., 2012)
SN1...S = ½(3 < cos
2θ > −1) (2)
Drug water-membrane partition coefficients were calculated as
(Vorobyov et al., 2012):
K(wat → mem) =
1
z2 − z1
z2∫
z1
e
−
{W(z)−W(z1)}
kBT dz (3)
whereW(z) is the PMF, z1 and z2 are points in aqueous solution
on opposite sides of the membrane, kB is Boltzmann constant,
and T is the absolute temperature. Partitioning free energies were
calculated as
1G(wat → mem) = –kBT ln K(wat→ mem) (4)
Error bars were estimated from PMFs by propagation of
uncertainties.
To estimate the 1D diffusion constant in the z direction,D(zi),
we analyzed the corresponding US windows with Hummer’s
method (Hummer, 2005):
D(zi) =
〈
δz2
〉
i
τi
(5)
where
〈
δz2
〉
i
and τi are the mean square deviation from the
average position and the position correlation time for US
window i.
τi = lim
s→0
τi(s) = lim
s→0
Cˆz(s; zi)〈
δz2
〉
i
= lim
s→0
∫∞
0 e
−st
〈
δz(t)δz(0)
〉
i
dt〈
δz2
〉
i
(6)
Cˆz(s; zi) is the Laplace transform of the position autocorrelation
function Cz(t; zi):
Cˆ z(s; zi) =
∫ ∞
0
e−stCz(t; zi) dt (7)
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where Cz(t; zi) =
〈
δz(t)δz(0)
〉
i
, s is the inverse time and δz =
z − 〈z〉i is the drug COM position displacement.
Values of τi(s) were calculated at s-values 0.01, 0.02, . . . , 0.1,
0.2, . . . , 1.0, 2.0, . . . , 10.0 ps−1. τi(s) were extrapolated to s= 0 by
fitting the function a/(s+b), where a and b are parameters, in the
s range from 0.02 to 1.00 ps−1. See our previous study (Vorobyov
et al., 2014) for more details.
Based on PMF and diffusion coefficient profiles we computed
water-membrane drug permeability rate as,
P =
(∫ L/2
−L/2
exp(Wz/kBT)
D(z)
d z
)−1
(8)
an integral over the local bilayer resistance (Marrink and
Berendsen, 1994), spanning−14≤ z ≤14 Å for SotN and−20≤ z
≤20 Å for SotC (with PMF-values adjusted to be 0 at the borders),
where the drug is expected to cross a central barrier; essential
for modeling permeation via a single molecule PMF (Roux and
Karplus, 1991). This description assumes we are in the diffusion
limit, where the mean velocity is proportional to the mean force,
which is valid if the drug displacement correlation length is short
compared to the spatial variations in the force (Marrink and
Berendsen, 1994).
RESULTS
Comparative Ionized Drug Membrane
Partitioning
First, we studied membrane partitioning of SotC and compared
it to the partitioning of CisC and MoxZ, each drug form
representing the dominant protonation state in aqueous solution
at the physiological pH. We studied their translocation across
POPC membranes using US MD simulations, which allow
for more efficient sampling of energetically unfavorable drug
distributions across a lipid membrane compared to conventional
unbiased MD simulations. US works by restraining drug
positions at different values of z across the membrane using a
harmonic potential. Thus, we can compute free energy for drug
positions along the bilayer normal, with z = 0 corresponding to
membrane center.
When all 3 drugs are located near z = 0 (see Figure 1A),
we observed substantial membrane deformations, where they are
coordinated by water molecules and lipid headgroups from one
(for CisC) or both (for SotC and especially for MoxZ) membrane
interfaces. Not surprisingly, such membrane deformations lead
to substantial energetic penalties for ionized drugs tomove across
the membrane with the peak values at z = 0: around 18 kcal/mol
for MoxZ, 10 kcal/mol for SotC and just 5 kcal/mol for CisC.
Interestingly, such differences in peak free energy values correlate
with computed MM drug dipole moments, which are 41.3 Debye
for MoxZ, 15.5 Debye for SotC and 6.8 Debye for CisC for the
same drug molecule “standard” positions and orientation (as
defined by Gaussian software). For MoxZ, extensive membrane
deformation exhibited by both leaflets are due to the positively
charged ammonium and negatively charged carboxylate moieties
at opposite ends of the molecule (Figure 1C). For SotC, a cationic
secondary ammonium and polar sulfonamide groups can also
attract watermolecules or lipid headgroups. Both SotC andMoxZ
can stretch along the membrane normal to interact with both
bilayer interfaces. However, the situation is different for CisC,
which also has several polar functional groups and a positively
charged tertiary ammonium functionality at the center of the
molecule, but it is floppier than those drugs and seems to be
attracted to one membrane interface (see Figure 1). Also, CisC
has a pronounced binding trough of around −3 kcal/mol at
14 ≤ |z| ≤ 17 Å. This suggests, that unlike SotC and MoxZ it
will accumulate at water—membrane interface. The presence of
the binding trough will also inadvertently increase a barrier a
drug will need to overcome to cross a membrane from ∼5 to 8
kcal/mol (see Figure 1B). These calculations suggest fairly high
but surprisingly different energetic costs to cross the membrane
for this collection of ionized molecules.
Models of d-Sotalol
We performed a more detailed analysis of different protonation
states of d-sotalol, focusing on the energetics of its membrane
crossing. Like many other drugs in aqueous solution, d-sotalol
can exist in several protonation states depending on solution pH
and other factors, such as proximity to specific protein residues.
Data from the literature indicate that aqueous pKa-values for d-
sotalol are 8.3 and 9.8 attributed to deprotonation of sulfonamide
and secondary ammonium functionalities, respectively (Foster
and Carr, 1992; Hancu et al., 2014). This indicates that at
physiological pH 7.4, SotC is the predominant form (around
89%), while deprotonation of the sulfonamide functionality leads
to a second dominant SotZ form (around 11%). At more basic
pH, the secondary ammonium functionality will deprotonate
as well, leading to a negatively charged, anionic form SotA
(Figure 2).
However, there is yet another possibility, in which
deprotonation of secondary ammonium group occurs first,
leading to a neutral d-sotalol form (SotN). In fact, there is
likely an equilibrium, and possibly interconversion, between
SotN and SotZ forms, in which either one is favored depending
on the polarity of the surrounding medium. We expect that
a substantially less polar SotN form would be favored in the
hydrophobic environment of the lipid membrane interior based
on our MoxZ simulations discussed above, whereas a more
polar SotZ might be favored in aqueous solution. Unfortunately,
there are no experimental data to address this issue for d-sotalol.
We performed a series of implicit solvent QM calculations,
which seem to indicate slight preference for SotN even in bulk
water (see Supplementary text for more information), but their
accuracy is very uncertain. However, a recent experimental
study using a combination of potentiometric titration and
spectrophotometry measurements has suggested around 90%
of zwitterionic and 10% of neutral form of moxifloxacin is
present at physiological pH range, and that only a neutral form
contributes to drug partitioning into a non-polar environment
of lipid membranes or 1-octanol often used as a membrane
mimetic (Langlois et al., 2005). This suggests that a neutral form
of a drug is likely the one to undergo an unassisted membrane
translocation.
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FIGURE 1 | Ionized drug translocation across a POPC membrane. (A) Representative snapshots from a central (z = 0) umbrella sampling windows for cationic
d-sotalol (SotC), cationic cisapride (CisC), and zwitterionic moxifloxacin (MoxZ). Drug molecules along with lipid P atoms (orange), K+ (purple) and Cl− (cyan) ions are
shown in a space-filling representation. Other elements are colored as follows: C—gray, H—white, O—red, N—blue, S—yellow. Water molecules are shown as tubes
and lipid tails as wireframes. (B) PMF profiles for POPC membrane crossing for 3 drugs shown in (A). Error bars represent measures of asymmetry. (C) Chemical
structures of those drugs drawn using MarvinSketch program.
Since we are particularly interested in lipophilic access of
cardiotoxic drugs known to block hERG, we have developed
standard CHARMM (Klauda et al., 2010) compatible models of
d-sotalol in charged (SotC) and neutral (SotN) forms. The QM
and MM dipole moments for those d-sotalol forms and drug—
water interactions probed for the model optimizations are shown
in Figures 3A,B for SotN and SotC, respectively. Optimized
CHARMM charges (Table S3) provide good agreement with
QM target dipole values. The optimized MM dipole moments
point in same direction (<1◦ difference in angle between QM
and MM for both SotC and SotN) and are each within 20%
difference in magnitude (SotN 6%, and SotC 14%). The water
interaction distances were all within 0.4 Å of QM target values
(see Tables S4, S5). The dipole moment is significantly higher
for SotC (17.64 Debye), than for SotN (5.98 Debye), as is to
be expected for charged vs. neutral species and in agreement
with QM-values. Interaction energies with water were also in
good agreement with QM-values with root mean square (RMS)
and maximum errors of 0.8 and 1.5 kcal/mol for SotN (Table
S5) as well as 1.6 and 3.0 kcal/mol (see Table S4) for SotC,
respectively. No internal (bond, angle, dihedral angle) parameters
needed to be optimized for SotC, whereas for SotN there was
a high penalty score for the C2-N1-C3 bond angle (shown by
blue arrow in Figure 3C), and optimization yielded a difference
of 0.86◦ (i.e., <1◦ as required) between MM and QM values.
Also for SotN, 7 dihedral angle parameter optimizations yielded
marked improvement over CGENFF initial guesses (illustrated in
Figure 3C for SotN C8-C3-N1-C2 dihedral angle highlighted in
pink, with all the dihedral scan profiles shown in Figure S2), with
optimized torsional energy minima within ∼0.5 kcal/mol of QM
values. For comparison, raw CGENFF dihedral parameters with
high penalties yielded QM energy minima differences sometimes
as high ∼2 kcal/mol. These optimized parameters represent a
significant improvement over initial guesses and should yield
more accurate computed energetics from MD simulations.
At this time, we were not able to develop empirical models of
the SotZ and SotA forms of the drug (Figure 2), since a negatively
charged sulfonamide nitrogen atom type does not exist in either
CHARMM biomolecular, or generalized (CGENFF) force fields.
The fraction of these forms in aqueous solution or other media
is uncertain, but based on a very high free energy barrier for
zwitterionic moxifloxacin translocation (Figure 1 and discussion
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FIGURE 2 | Protonation states of d-sotalol. Chemical structures were drawn using ChemDraw program. Asterisk (*) indicates chiral C atom.
above) as well as the very large dipole moments for SotZ and SotA
(see Table S1 and Supplementary text), we do not expect them
to contribute substantially to the passive diffusion of d-sotalol
across a lipid membrane, or the lipophilic access of this drug to
hERG or other protein targets.
We should also mention that sotalol has a chiral center at
C1 atom (shown by an asterisk in Figures 2, 3C), and in this
study we only focused on S-enantiomer, d-sotalol. However,
the developed force field parameters can be also used for R-
enantiomer, l-sotalol, which will be also considered in our
subsequent studies.
d-Sotalol Solvation and Orientation across
the Membrane
We used our SotC and SotN models to investigate their
interactions with a lipid membrane as they move across
using US MD simulations. For those simulations we applied
extensive sampling, especially important for hindered drug
reorientation in the membrane interior (see Supplementary text
for more information). We also performed those simulations
with two popular biomolecular modeling packages, NAMD and
CHARMM,with the former beingmore computationally efficient
on our GPU (Graphics Processing Unit) cluster. However,
CHARMM allows using P21 symmetry to take into account likely
changes in the areas of top and bottom bilayer leaflets as a
drug moves through the membrane by shuffling lipid molecules
between them as it happens. We established that the lipid
membrane properties of our simulated systems are in agreement
with experimental data in this case (See Supplemental text).
We then started to investigate membrane—drug interactions,
first, by looking at equilibrated system snapshots at the
membrane center (z = 0 Å) and water/membrane interfacial
region |z| = 14 Å, corresponding to free energy minimum for
SotN (see Figure 4). It can clearly be seen that both charged
and neutral drug molecules can adapt different orientations
with respect to the membrane normal and can be solvated by
both water molecules and lipid head groups even deep in the
membrane interior for SotC in agreement with our CHARMM
multiple-drug simulations shown in Figure 1 and discussed
above. Interestingly, that in NAMD simulation snapshots shown
in Figure 4, we observed that SotC while held around membrane
center (z = 0) can adopt different long-lasting (see below)
orientations “grabbing” water molecules and lipid head groups
from either top or bottom membrane interface, but did not
observe them making interfacial connections to both leaflets, as
was observed in our CHARMM simulations (Figure 1).
Next, we performed a quantitative analysis of drug solvation
shown in Figure 5.While SotC and SotN are found in bulk water
regions, for |z|> 25 Å (∼5 Å beyond phosphate groups), they are
solvated by∼5.5 and 5 water molecules, respectively. We defined
the interfacial region as 15 < |z| < 25 Å, where 15 Å boundary
was established based on an experimentally determined POPC
hydrophobic thickness of 28.8 ± 0.6 Å (Kucerka et al., 2011).
The water coordination remains the same as in bulk, until
the drug reaches inside the core of the membrane, where we
observe a bigger drop in the number of water molecules solvating
SotN. In the center of the bilayer, at z = 0 Å, almost no water
molecules are found coordinating the neutral drug, while at
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FIGURE 3 | CHARMM force field parameter optimization of d-sotalol. The QM (blue arrow) and MM (red arrow) dipole moments for neutral, SotN (A), and charged,
SotC (B), forms of d-sotalol are compared, and their QM optimized water interactions are shown by dashed blue lines. A sample dihedral angle C8-C3-N1-C2
optimization (bonds are highlighted in purple on SotN molecule) is shown in (C), with reference QM computed energy scan in blue, non-optimized CGENFF energy
scan in green, and optimized MM energy scan in red, demonstrating marked improvement. Asterisk (*) indicates chiral C atom (C1).
least 1.2 water molecules continue to coordinate the charged
species. Additionally, when SotC is found at the interface or the
hydrophobic core of the membrane, it is coordinated by lipid
phosphate and carbonyl groups, while SotN remains virtually
uncoordinated by these functional groups in the membrane core
and has a similar coordination by carbonyl O and smaller by
phosphate O atoms in the interfacial region (Figure 5).
Such solvation results in the preferential orientation of both
SotC and SotN with respect to bilayer normal (coinciding with
the z axis) as shown in Figure 6. There is no preferred orientation
of both drugs in bulk water as expected, which is exemplified
by average θ being around 90◦ and order parameter being 0
(see Figure 6 and top right panels in Figures S7, S8 for time
series). There is a strong preference for N1...S vector of both
drugs to be aligned with the z axis in the outer interfacial region
i.e., at 20 < |z| <25 Å, whereas there is some tendency for
drugs to lie perpendicular to the membrane normal i.e., in the
membrane plane (with order parameter S < 0) in the inner
interfacial and outer core regions at 10 < |z| < 20 Å (see
Figures S7, S8 for time series). In the inner core region (|z| <
10 Å) the drugs again become aligned or anti-aligned with the
z-axis. Interestingly, the orientation of SotN and SotC in the
inner interfacial and core regions seem to be opposite—with
SotC favoring parallel orientation and SotN—antiparallel with
the membrane normal for the drug positions with the negative z-
values (Figure 6). This results from different relative affinities of
SotC and SotN functional groups: the cationic ammonium group
in SotC strongly attracts water molecules and lipid head groups,
whereas its deprotonation makes its sulfonamide functionality a
better attractor leading to this functional group re-orientation
to be closer to the membrane interface. These interactions lead
to hindered rotation (see Figures S7, S8) on the time scale of
MD simulations we performed here (10–15 ns for each drug
z) leading to difficulties sampling thermodynamics of drug—
membrane interactions discussed below (see Supplemental text
for more details).
d-Sotalol Energetics and Protonation
across the Membrane
We computed free energy profiles for SotC and SotN moving
across a POPC membranes based on analysis of drug position
fluctuations around restrained z positions in US MD simulations
as described above. Those profiles are shown in Figure 7A for
both NAMD and CHARMM simulations. For SotN, differences
between NAMD and CHARMM free energies are within
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FIGURE 4 | Representative snapshots of charged (SotC) and neutral (SotN) d-sotalol moving across a POPC membrane from umbrella sampling MD simulations.
Reference d-sotalol center of mass (COM) z positions with respect to membrane COM are shown on the top. See Figure 1 caption for molecular representation and
coloring information. Two structures for z = 0 for each drug represent final system snapshots from two independent simulations with a different initial drug orientation
(see Supplementary text for more information).
uncertainties (shown as error bars in Figure 7A), obtained as
measures of profile asymmetries (see Figure S9 and Supplemental
text). However, for SotC the free energy barrier is ∼3 kcal/mol
smaller for CHARMM (11.2± 1.1 kcal/mol) compared to NAMD
(14.4± 0.1 kcal/mol). Such free energy decrease along with a flat
free energy profile for |z| < 3 Å can be due to P21 point group
transformations used in CHARMM simulations. This is also in
line with interfacial connections to both bilayer interfaces seen in
these simulations (see Figure 1 and discussion above). However,
relatively large asymmetries of up to ∼2 kcal/mol (Figure S9)
preclude us from an unambiguous assignment of this difference.
If we compare SotC and SotN free energy profiles shown in
Figure 7A, we will see differences such as substantially higher
central peak for SotC, e.g., 14.4 vs. 5.4 kcal/mol for SotN from
NAMD simulations, as well as presence of a deep interfacial
minimum of−2.8 kcal/mol for SotN at |z|= 14 Å, similar to one
seen for cationic cisapride (Figure 1 and discussion above). Such
minimum indicates a substantial neutral drug accumulation at
the water-membrane interface. Interestingly, there is practically
no such minimum for SotC, although, a shallow ∼-1 kcal/mol
trough can be seen on a not-symmetrized PMF profile in Figure
S9. The substantial difference in peak heights for SotC and SotN is
not unexpected, however, and was also observed for basic amino
acid side chains in our previous simulations (Li et al., 2008, 2013).
It can be explained by different molecular mechanisms governing
SotC and SotN permeation: substantial membrane deformations
for the former and nearly complete drug dehydration for the
latter (Vorobyov et al., 2010, 2014; Li et al., 2012, 2013). Based
on free energy difference between charged and neutral drug
forms we can also approximate pKa shift and thus preferred
protonation form of a drug across the membrane:
1pKa = 1/(2.303kBT) {1WSotN(z)−1WSotC(z)} (9)
where kB is Boltzmann constant, T—absolute temperature and
1W (z) are position-specific free energies for charged and neutral
d-sotalol. Corresponding 1pKa profiles are shown in Figure 7B
and indicate rapid downward 1pKa shifts soon after the drug
gets into contact with membrane. Near the membrane center
1pKa reaches about −6.5 for NAMD and −4.5 for CHARMM
based calculations, with the latter estimate being smaller due
to a ∼3 kcal/mol smaller SotC free energy barrier discussed
above. Qualitatively, both results are similar and indicate rapid
drug deprotonation soon after a drug starts moving across a
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FIGURE 5 | Analysis of d-sotalol solvation from umbrella sampling MD
simulations. Solvation numbers of water or lipid oxygen atoms within 4.25 Å
cutoff distance from non-hydrogen atoms of SotC or SotN were computed
based on integrated radial distribution function (RDF) profiles. See Figure S6
for a few representative RDF profiles. Error bars shown in all the graphs are
computed from profile asymmetries.
membrane. In fact, considering its first aqueous pKa of 8.3, even
getting as close as 20 Å to the membrane center will already lead
to drug deprotonation. However, it should be noted that we have
not considered a possible role of a zwitterionic d-sotalol form,
SotZ, in this equilibrium.
d-Sotalol Water-Membrane Partitioning
and Permeations: Connection to
Experiments
Next, we need to attempt connecting our findings to
experimental observables such as water—membrane partitioning
coefficient K and permeability rate P. All the relevant data are
summarized in Table 1. There is an experimental estimate for
water—dimyristoylphosphatidylcholine (DMPC) membrane
K′(wat→mem) of 2.50 obtained at 303K (Redman-Furey and
Antinore, 1991). This is an apparent value, which takes into
account a pH-dependent fraction of membrane-active drug
species at those conditions. However, since we know that
only SotN is expected to accumulate in the membrane we can
compute an intrinsic K-value at experimental pH = 7.2 using
drug aqueous pKa = 8.37 and Henderson-Hasselbach equation
to obtain K(wat→mem) = 2.50 ∗ 10(8.37−7.20) = 37.0. And
corresponding partitioning free energy is 1G(wat→mem) =
−RT ln K(wat→mem) = −2.17 kcal/mol. These estimates,
again, do not take into account a presence of SotZ form in the
drug protonation equilibrium, which will likely further increase
K-value and decrease corresponding 1G. Nevertheless, we
can compare experimental estimates with values we computed
from NAMD US free energy profiles using Equations (3) and
(4). Estimated K(wat→mem) and 1G(wat→mem) values for
SotN of 13.4 ± 8.6 and −1.6 ± 0.4 kcal/mol (see also Table 1),
respectively, are in good agreement with experiment also
considering a different lipid (POPC vs. DMPC) and temperature
FIGURE 6 | Analysis of d-sotalol tumbling during umbrella sampling MD
simulations. (A) Average polar angle θ distribution for N1...S d-sotalol vector
with respect to the z axis for charged (SotC, blue) and neutral (SotN, red) drug
moving across POPC membrane. (B) Corresponding order parameter profiles
for this vector with respect to the z axis. Error bars shown in all the graphs are
computed from profile asymmetries. See Figures S7, S8 for a few
representative θ(N1...S) time series.
(310 vs. 303K) used in simulations and experiment. Estimates
from CHARMM simulations (Table S6) are similar, within an
error of NAMD values. As expected, SotC does not accumulate
in the membrane, with K(wat→mem) and 1G(wat→mem) of
0.69± 0.36 and 0.23± 0.0.28 kcal/mol, respectively (Table 1).
MD simulations of water-membrane partitioning are a good
test of the drug model accuracy, and can predict how much
drug accumulates in the membrane compared to bulk water.
However, it does not consider the kinetics of drug movement
across a membrane, which is also essential for predicting its
pharmacology and toxicology. Permeability rates, P, provide
corresponding estimates and are measured experimentally using
different cell lines such as caco-2 or artificial membrane systems
such as PAMPA (Parallel Artificial Membrane Permeability
Assay) (Bermejo et al., 2004). Experimental estimates for d-
sotalol P are available from a recent study (Liu et al., 2012)
with a PAMPA P-value of 3.2 × 10−7 cm/s. A direct comparison
between experimental and computed P values is known to be
challenging, with many complicating factors precluding direct
quantitative assessment of absolute values (Carpenter et al., 2014;
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FIGURE 7 | Analysis of d-sotalol thermodynamics from umbrella sampling MD
simulations. (A) Free energy or potential of mean force (PMF) profiles for
charged (SotC, blue and cyan) and neutral (SotN, red and orange) d-sotalol
moving across a POPC membrane. In CHARMM simulations (cyan for SotC
and orange for SotN) P21 symmetry was used. See text for more details. (B)
d-sotalol pKa shifts computed from PMFs in (A).
Di Meo et al., 2016; Bennion et al., 2017). Nevertheless, we
computed P estimates for both SotC and SotN using Equation
(8) as was done in our previous study (Vorobyov et al., 2014)
based on free energy and diffusion coefficient profiles. The
latter, shown in Figure 8, were obtained based on correlation
times and mean fluctuations of drug COM in z direction using
Equation (5) as was also done previously (Vorobyov et al.,
2014). The computed diffusion coefficient profiles indicate a
rapid 10-fold drop of diffusion coefficients for both SotC and
SotN as drug molecules start interacting with lipid membranes,
similar to many previous observations (Carpenter et al., 2014;
Vorobyov et al., 2014). Interestingly, diffusion coefficients for
SotC and SotN are similar, both in water and in the membrane
interior (Figure 8 and Table 1), despite difference in net charge
and very different drug—membrane interactions. Computed P-
values, presented in Table 1 as log P of −8.57 for SotC, and
−4.43 for SotN encompass an experimental estimate of −6.50.
Based on those values alone, we cannot comment on accuracy
of our prediction, and comparison with values for other drug
molecules (desirably, with similar functionalities) as was done in
a recent study (Bennion et al., 2017) would be the best. What our
computed values indicate though, that a neutral drug is about
FIGURE 8 | Analysis of d-sotalol diffusion from umbrella sampling MD
simulations. Diffusion coefficient profiles are computed as described in the
text. Error bars shown are computed from profile asymmetries.
TABLE 1 | Water-membrane partitioning and permeability data from umbrella
sampling MD simulations for charged (SotC) and neutral (SotN) d-sotalol
translocation across a POPC membrane using NAMD.
Experiment Umbrella sampling MD simulations
SotC SotN
W(peak), kcal/mol 14.38 ± 0.14 5.43 ± 0.53
|z(peak)|, Å 0.0 0.0
W(well), kcal/mol −0.16 ± 0.10 −2.79 ± 0.47
|z(well)|, Å 32.5 14.0
W(barrier), kcal/mol 14.54 ± 0.17 8.22 ± 0.71
1G(wat->mem),
kcal/mol
−2.17a 0.23 ± 0.28 −1.60 ± 0.37
K(wat->mem) 37a 0.69 ± 0.36 13.41 ± 8.58
D(wat), 10−5 cm2/s 0.99 ± 0.14 0.98 ± 0.06
D(mem), 10−5 cm2/s 0.061 ± 0.039 0.087 ± 0.020
log P(wat->mem),
[log cm/s]
−6.50b −8.57 −4.43
aRedman-Furey and Antinore (1991) using pKa = 8.3 to compute intrinsic values based
on observed apparent K′(wat→mem) of 2.50.
bLiu et al. (2012) using measured PAMPA permeability rate.
4-orders of magnitude more permeable compared to a cationic
one, and that both values are within few orders of magnitude of
an experimentally observed permeability.
d-Sotalol—Membrane Interactions: Effect
of Anionic Lipids
Thus far, we only considered d-sotalol partitioning across a
POPC membrane using US MD simulations for a single drug
molecule. However, we also tested if lipidmembrane composition
affects drug—lipid interactions. In fact, cardiomyocyte
lipid membrane is known to host multiple lipid types: in
addition to dominant zwitterionic phosphatidylcholine and
phosphatidylethanolamine, it also has a substantial fraction of
anionic lipids—phosphatidylserine, phosphatidylinositol and
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phosphatidic acid [6–13% in human (Post et al., 1995) or 17–18%
in feline cardiac cells (Leskova and Kryzhanovsky, 2011) based
on total phospholipid content]. Anionic lipids are expected to
increase membrane binding affinity for cationic drug forms and
other cations, as was evidenced by our previous study where we
saw increase in the interfacial binding for a positively charged
arginine side chain analog, methyl guanidinium, in the presence
of an anionic lipid phosphatidylglycerol (Vorobyov and Allen,
2011). The possible effect of anionic lipids on neutral drug
binding is less clear and is worth testing as well. Therefore,
we performed simulations of both SotC and SotN in lipid
membranes containing 15% POPS and 85% POPC, respectively,
and compared the results to corresponding drug simulations
with pure POPC membranes.
We used 500 or 1000 ns long unbiased MD simulations
with multiple (15–16) drug molecules initially placed in bulk
aqueous solution, corresponding to∼40mMdrug concentration.
Most SotN molecules become bound to the lipid membrane
within 200 ns for the simulation with pure POPC and around
400 ns with a POPC/POPS mixture (see Figure S11). The
equilibrium aqueous concentration of SotN drops to ∼8mM
for POPC/POPS and ∼5mM for a POPC only system. For
systems containing SotC,most drugmolecules remain in aqueous
solution throughout the simulations with only ∼4 (out of 15)
interacting with membrane regardless of the lipid composition
(Figure S11). Equilibrated systems are shown in Figure 9C
demonstrating substantial membrane binding of SotN but not
of SotC. Drug probability distributions from those simulations,
computed based on simulation data after equilibration (which
was achieved in 200 or 400 ns), are shown in Figure 9A. These
data confirm the picture demonstrating substantial interfacial
binding for SotN with well-defined probability maxima around
|z| = 15 Å for both POPC and POPC/POPS systems. No
interfacial binding was detected for systems containing SotC
(Figure 9A). In the cationic sotalol system with POPS present,
there is a slightly increased accumulation of the drug density in |z|
range of 15–30 Å compared to a systemwith POPC only. This can
be due to expected attraction between anionic lipid head groups
of POPS and positively charged SotC moieties. However, the
effect is small and is thus unlikely to be physiologically significant
in this case.
The probability distributions shown in Figure 9A can be
converted to free energy profiles as 1G(z) = –kBT ln ρ(z),
where ρ is probability density, kB is Boltzmann constant, and
T is the absolute temperature (see also analogous Equation
4 above). Those profiles are shown in Figure 9B and are in
general agreement with those from US MD simulations shown
in Figure 7A previously. As expected, we did not observe SotC
located near the membrane center during 500 ns of unbiased
MD simulations, and therefore free energy profiles are not
defined in this region. However, we observe that the slope
of the profile is steeper in the presence of POPS, suggesting
a higher translocation barrier and hence slower translocation
in this case. SotN molecules were distributed throughout the
membrane, and thus we could compute complete free energy
profiles including central peaks. Interestingly, there are shallower
interfacial binding troughs (by 0.5–0.6 kcal/mol at |z| =
14–15 Å), higher central peak (by ∼1.1 kcal/mol) and thus
larger translocation barriers in the presence of POPS, indicating
less favorable membrane binding and slower translocation rates
for SotN. Upon comparison of SotN free energy profiles from
US and unbiased MD simulations, shown in Figure 7A, 9B,
respectively, we observed a substantially smaller central free
energy peak (by 3.7 kcal/mol) and shallower interfacial binding
(by 0.6 kcal/mol) in unbiased simulations. There are several
factors which can contribute to such differences, including
multiple drug molecules, larger membrane patch, and presence
of applied electric field in unbiased MD simulations, all of which
can possibly lead to smaller permeation barriers. A detailed
elucidation of these and other factors is beyond the scope of this
study and will be investigated in our subsequent works.
DISCUSSION
Exploring Ionized Drug Membrane
Partitioning
At physiological pH many cardiac channel blockers exist
in aqueous solution mostly in their cationic form for d-
sotalol and cisapride, and zwitterionic form for moxifloxacin
(ionized, but with net zero charge). Our MD simulations have
demonstrated that all of them cause substantial membrane
deformations, with lipid head groups and water molecules
coordinating them deep into the hydrophobic membrane
core. Large free energy barriers occur at the center of the
membrane as a result of the deformations, making such mode
of drug translocation unlikely. Moreover, ionized d-sotalol and
moxifloxacin do not demonstrate any interfacial membrane
binding, indicating that they will not be accumulating there,
and thus limiting their protein target accessibility through
this route. Interfacial membrane binding is, however, possible
for cationic cisapride, and its accumulation there could play
a role in its pharmacological profile. However, to provide a
more complete picture for drug membrane translocation and
membrane-mediated protein target affinity, additional less-polar
drug protonation states should be considered. This is what we
did for d-sotalol; a prominent example of high-arrhythmia risk
hERG blocker. At a physiological pH of 7.4, 89% of this drug
exists in a cationic form, indicating a ∼1.3 kcal/mol energetic
penalty for its deprotonation, which can be easily overcome by
the hydrophobic environment of lipid membranes that provide a
barrier for charged and polar species (Gennis, 1989).
Computing Charged and Neutral d-Sotalol
Membrane Partitioning
In addition to a cationic d-sotalol force field model, we
developed parameters for one of the neutral forms of d-
sotalol. SotN is substantially more lipophilic, as expected,
with a free energy penalty near the membrane center of
∼5 kcal/mol, compared to ∼15 kcal/mol barrier for the
cationic species, which, interestingly, correlates with the
ratio of their dipole moments. Moreover, unlike SotC, SotN
accumulates at the water-membrane interface, making it
accessible for binding to protein targets through the lipophilic
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FIGURE 9 | Analysis of d-sotalol partitioning in the presence of anionic lipids from unbiased MD simulations. (A) Probability density and (B) free energy or potential of
mean force (PMF) profiles for charged (SotC) and neutral (SotN) d-sotalol moving across a 100% POPC lipid bilayer (cyan and yellow for SotC and SotN, respectively)
or a bilayer composed of an 85% POPC and 15% POPS lipid mixture (green and magenta for SotC and SotN, respectively). (C) Molecular snapshots of equilibrated
SotN+POPC, SotC+POPC, SotC+POPC/POPS systems after 500 ns, and SotN+POPC/POPS system after 1000 ns of unbiased MD simulations on the Anton 2
supercomputer. P atoms of POPC and POPS lipids are shown as orange and green balls, respectively. See Figure 1 caption for other molecular representation and
coloring information.
pathway. Such accumulation, which can be quantified by
water-membrane partitioning coefficient, K(wat→mem), is
in agreement with experiment (within an uncertainty, see
Table 1), suggesting a good quality of the developed empirical
model.
Also, SotN does not lead to substantial membrane
perturbations; it transiently coordinates with only a few
water molecules as it moves across a hydrophobic core
of a membrane, unlike SotC. This entails different molecular
mechanisms of membrane translocation: a traditional “solubility-
diffusion” for SotN governed by drug dehydration, and so called
“ion induced defect” for a cationic form, where a cost of
membrane deformation plays a major role as was suggested
in our previous studies on charged amino acid side chain
and small hydrophilic ion translocation (Li et al., 2012;
Vorobyov et al., 2014). Thus, we can expect very different
dependence of their membrane translocation energetics on
lipid membrane composition, such as a strong decrease with
a corresponding reduction in membrane thickness for SotC,
but not for SotN. This is why we expect good agreement with
experiment for SotN water-membrane partitioning despite
using a different lipid bilayer (POPC vs. DMPC). Translocation
of SotC, however, is expected to be very sensitive to the
mechanical properties of membrane such as thickness, as
well as the presence of cholesterol, or polyunsaturated fatty
acid tails, which can increase or reduce membrane rigidity,
respectively (Feller et al., 2002; Pitman et al., 2004). Our
computed membrane translocation energetics for charged
cisapride and neutral d-sotalol across POPC membrane are
very similar, but we expect a larger barrier for cisapride in
thicker and/or cholesterol-containing membranes. This will lead
to different modulation of drug accessibility for intracellular
and membrane-located protein targets. As a first step toward
the investigation of lipid composition dependence, we briefly
examined the role of anionic lipids in water-membrane d-sotalol
partitioning energetics. Despite expected more favorable drug
membrane binding in the presence of POPS, we observed an
opposite trend with shallower interfacial troughs for SotN
and larger translocation barriers for both SotN and SotC.
This indicates that such modulation can be due to specific
drug—membrane interactions rather than a general electrostatic
attraction.
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Estimating d-Sotalol Membrane
Permeation Kinetics
For SotC and SotN, we also provide estimates of membrane
translocation kinetics, expressed as permeability rates (P). SotN
has a translocation rate that is four orders of magnitude faster
than SotC (see Table 1), which is as expected from the difference
in their membrane translocation energetics, and similarly
reduced diffusion coefficients in the membrane interior. This is
in agreement with our previous estimations for ions (Vorobyov
et al., 2014) and other drugs (Boiteux et al., 2014). Based on the
computed P-values and the membrane thickness considered in
those calculations, we estimate that a single SotN molecule can
translocate between interfacial binding sites on opposite sides of
the membranes in about 7.5 × 10−3 s (millisecond time range),
whereas for SotC crossing membrane will take around 150 s.
SotN is expected to be accumulated in the membrane over 10-
fold compared to its equilibrium concentration in bulk aqueous
solution, which is why we are considering its permeation, even
though it is a minor component in the bulk aqueous solution
at the physiological pH, regardless of its unknown ratio to a
membrane-impermeable zwitterionic form. An experimental P
estimate for d-sotalol based on measurements using PAMPA
is in between our computed values for SotC and SotN (see
Table 1 and Liu et al., 2012). Yet, a direct numerical comparison
of our computed and experimental P estimates is extremely
challenging, as has been indicated in many previous studies (Orsi
et al., 2009; Carpenter et al., 2014; Di Meo et al., 2016; Bennion
et al., 2017). This is largely because experimentally measured
quantities mostly represent so-called apparent values, which
typically include contributions from different drug protonation
forms at experimental pH, depend on water layer thickness and
condition, and may encompass different drug permeation routes
(Bermejo et al., 2004; Avdeef et al., 2005; Ottaviani et al., 2006;
Orsi et al., 2009).More standardized intrinsic P-values for neutral
drug forms are typically harder to get (Bermejo et al., 2004;
Orsi et al., 2009), and even then, quantitative agreement with
MD computed values remains challenging due to substantial
differences between an experimental macroscopic system, and a
microscopic molecular model. Therefore, an agreement between
relative P-values for different drugs is typically sought (Orsi et al.,
2009; Carpenter et al., 2014; Bennion et al., 2017), which will be
explored in our future studies.
Predicting Possible Membrane-Mediated
Ion Channel Accessibility Pathways
One mode of ion channel block by drugs is through an
intracellular aqueous pathway, where a drug in the cytosol passes
through a channel lower gate, when it is open, and occludes a
channel pore (Hille, 2001). Another possible mechanism for ion
channel block is through a lipophilic route, which was observed
in a recent MD study for a local anesthetic, benzocaine, entering
a central pore of sodium voltage-gated channel NavAb via lipid-
facing channel openings (fenestrations) (Boiteux et al., 2014). In
the case of the hERG blocker d-sotalol studied here, SotN would
likely to be a dominant drug form binding to the channel via this
route, but it could become protonated again once it is in the pore.
Our recent combined experimental/computational studies of
pH- and state-dependent hERG block by another high-risk pro-
arrhythmic drug dofetilide (sharing the same functional groups
as d-sotalol, but more potent) suggested that drug protonation
equilibrium plays a crucial role in its channel binding affinity
(Wang et al., 2016). To the best of our knowledge, no such
studies have been done for d-sotalol yet. The experimentally
measured on-rate of d-sotalol binding to hERG is quite slow,
in the range of several minutes (Numaguchi et al., 2000). This
is consistent with our computed membrane permeation rate
for cationic d-sotalol form. Recent experimental studies using
cells pre-equilibrated with sotalol, i.e., after the drug crossing
cell membranes, demonstrate faster than 200ms hERG block
(Li et al., 2017; Windley et al., 2017), indicating that drug
membrane permeation could be a rate-limiting step considering
preferential drug channel access via the intracellular aqueous
pore. However, other reasons for such outcome, such as a
preponderance of a lipophilic channel access pathway from of
a local membrane bound pool of the drug, suggested by our
neutral d-sotalol simulations, are possible and can be tested by
additional experiments as well as comprehensive drug—channel
MD simulations. This along with pH-dependent measurements
can help elucidating roles of different drug protonation states and
their contribution to channel block.
Moreover, experimental drug—channel on-rates, which are
crucial components of functional scale kinetic models used for
in silico evaluation of pro-arrhythmia proclivities (as in the CiPA
initiative), can be corroborated using atomistic MD simulations,
such as those presented in this study. Moreover, atomistic MD
simulations can be used to identify different drug—channel
interaction pathways not easily discernable via experiment alone.
For instance, through comparison of computed rates for drug
membrane translocation and binding to the channel via aqueous
and lipophilic pathways, we can predict likely rate limiting step,
and relative contributions of all those processes to experimentally
measured rates, thus informing kinetic models and likely
improving their accuracy and predictive power. The spatially
resolved ionization-state-specific drug localization profiles and
water—membrane permeation rates computed here represent the
first crucial step toward this goal.
Further insight into structural determinants of drug-induced
channel blockade, including possible drug access pathways, can
be provided by comprehensive mutagenesis studies, similar to
one done recently for a large set of congenital long QT syndrome
2 associated hERGmutations (Anderson et al., 2014). Though not
directly related to drug-induced hERG block, several mutations
that were implicated in directly affecting channel gating or
permeation were for hERG residues facing the water-membrane
interface (Lees-Miller et al., 2015; Saxena et al., 2016), and
therefore would be easily accessible by drugs like neutral d-
sotalol, and cationic cisapride, that we explored in this study.
Even more importantly, similar computational approaches
can be used as one of the steps to design drugs, which have similar
membrane binding affinities and bind around mutated protein
residues that result in altered channel function. Such an approach
focusing on a desired drug lipophilicity and spatial arrangement
of crucial functional groups was used, for instance, to design
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selective sodium channel blockers (Muraglia et al., 2007; De Luca
et al., 2012; De Bellis et al., 2017). Such a structure-function based
approach was shown to improve drug safety profile through
mitigation of off-target effects, including hERG block (De Bellis
et al., 2017).
Limitations and Future Directions
Our study represents just a first step in atomistic-level elucidation
of thermodynamics and kinetics of cardiac channel blocking
drug translocation across a lipid membrane. We obtained
reasonable free energy profiles and water-membrane partitioning
coefficients with a moderate amount of sampling (10–15 ns per
umbrella sampling window or 0.8–1.2 µs for entire simulations).
In some cases, we had to run additional simulations with
alternative initial drug orientations to compensate for their
slow reorientation in the membrane interior observed in our
study. More extensive simulations for other drug membrane
partitioning using a different empirical force field and molecular
modeling software were reported recently (Bennion et al., 2017).
They can potentially provide improved accuracy provided a
high quality of an underlying empirical model and sufficient
sampling of drug tumbling, and thus can be considered as a viable
alternative of our approach. In our future studies we will also
test several alternative options for enhanced sampling (Bernardi
et al., 2015) such as metadynamics (Barducci et al., 2011), which
has been recently used in membrane partitioning simulations to
properly sample degrees of freedom orthogonal to the reaction
coordinate and thus provide a more accurate energetics (Jambeck
and Lyubartsev, 2013).
Alternatively, replica exchange simulations can be employed,
which can be especially useful for modeling mixed membrane
systems (Huang and Garcia, 2014). In our study, we mostly used
a one component lipid membrane containing POPC, whereas
lipid composition of cellular membranes is much more complex.
For instance, plasma membranes of cardiomyocytes (where
hERG channels are mostly located) has substantial fractions
of zwitterionic posphatidylcholine, phosphatidyethanolamine,
and sphingomyelin, negatively charged phosphatidylserine and
non-polar cholesterol with substantial differences in their
distribution between inner and outer leaflets (Post et al.,
1995). This is without taking into account lateral membrane
heterogeneity and existence of functional microdomains such
as lipid rafts and caveolae, suggested to influence cardiac
ion channel function (Maguy et al., 2006). At this time,
however, we are not yet in position to study such complex
heterogeneous systems via atomistic simulations, but coarse-
grained models, such as a popular MARTINI force field
(Marrink and Tieleman, 2013), are well-suited for such
investigations and can be potentially used for studying cardiac
drug interactions with realistic lipid membranes. In terms of
atomistic simulations, we are planning to extend our studies to
simulate drug partitioning to binary mixtures of phospholipids
and cholesterol, which is expected to substantially influence
ionizable drug partitioning and permeation, as discussed above.
Another direction, which we already started exploring here,
are binary mixtures of two phospholipids with different
head groups, possibly influencing drug permeation kinetics
and thermodynamics via specific interactions and/or altering
membrane physical-chemical properties.
Estimated drug permeation rates and their relation to
experimentally measured quantities remain uncertain as was
mentioned above. In this study we could only compare relative
values for cationic and neutral d-sotalol, which encompass
an experimental estimate. However, it is not clear if we can
simply relate those values to a measured apparent permeability
via computing effective resistances to permeation as was done
in a recent study (Carpenter et al., 2014). Another pertinent
issue is computing permeability rates for drug molecules with
pronounced interfacial binding (such as neutral d-sotalol in this
study), which will clearly increase a barrier height a drug will
need to hop over to permeate as was noted previously (Orsi et al.,
2009). Therefore, an expression for permeability rates (Marrink
and Berendsen, 1994) traditionally used for their calculations for
polar and ionic species, where free energies are referenced to bulk
aqueous solution, might not work anymore. In this study for
SotN we used a variant of this expression with free energy set to
0 at the interfacial binding site and computing permeability just
across a central barrier. A validity of such approximation remains
to be seen in more thorough investigations, e.g., by comparing
results with drug translocation rates computed from long
unbiasedMD simulations. Moreover, this approach does not take
into account drug translocation between the interfacial binding
site and bulk water. This contribution becomes dominant for
hydrophobic drugs such as general anesthetics (Vorobyov et al.,
2012), not considered in this study.
For d-sotalol and other hERG blockers with sulfonamide
functional group (e.g., dofetilide, ibutilide, E4031), an unresolved
issue is its anionic, deprotonated drug fraction, such as one
in the zwitterionic d-sotalol (SotZ). A neutral sulfonamide
group has been thoroughly parameterized recently and is
included in the generalized CHARMM force field (Yu et al.,
2012), whereas no atom type for anionic N or any associated
parameters are available to the best of our knowledge. For
d-sotalol in water at the physiological pH, a cationic form
with a neutral sulfonamide group is a dominant form, with
SotZ and/or SotN having a ∼11% contribution. Based on
our prediction, only SotN can move across a membrane, but
we need to know SotZ and SotN ratios in order to relate
computed membrane partitioning energetics to experimental
observables. Moreover, SotZ can be potentially an important
contributor to hERG binding through the interactions of
its negatively charged sulfonamide functionality with basic
residues in the voltage-sensing domain (VSD) of a channel,
for example. Such interactions were revealed in a recent
crystallographic/electrophysiological study in a VSD of a
voltage gated Nav1.7/NavAb chimera channel, where an anionic
sulfonamide “warhead” directly and selectively interacts with a
gating charge carrying arginine residue, immobilizing a voltage
sensor in its activated state (Ahuja et al., 2015). Whether a similar
binding motif is possible for hERG remains to be seen, but
it should not be discounted, and thus accurate empirical force
field for an anionic sulfonamide functionality will need to be
developed and can be validated on predicting an aforementioned
drug—channel interaction.
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Sotalol is a chiral molecule, and in this work we only studied
one enantiomer: d-sotalol, which was used in an infamous
SWORD clinical study (Waldo et al., 1996) mentioned above.
Sotalol enantiomers can be synthesized and separated (Carr et al.,
1991; Foster and Carr, 1992; Brodfuehrer et al., 1997), however,
a racemic mixture of d- and l-isomers has been used in many
biophysical, physiological and pharmacological experimental
studies up to date. l-sotalol is known to have some beta-blocking
activities, whereas d-sotalol seems to be inert (Gomoll and
Bartek, 1986) (a reason why it was used for SWORD study), but
they share very similar electrophysiological properties, including
QT prolongation (Touboul, 1993; Manoach and Tribulova,
2001). Even though interaction between two chiral molecules,
e.g., sotalol and lipid, can be different for stereoisomers (and used
for their separation), we do not expect substantial changes for
l-sotalol—membrane interactions as they are mostly governed
by dehydration for a neutral drug or membrane deformation
by a charged drug electric field. Therefore, simulations with d-
sotalol should be sufficient, however, a more complex situation
will arise for drug—channel interaction simulations, where both
stereoisomers might need to be tested.
Nevertheless, despite the limitations of this study, related
to tested drug and membrane models, our work demonstrated
good agreement between computed and experimental data, and
can definitely be used to predict the molecular mechanisms,
energetics and kinetics of drug-membrane interactions, and
potentially ion channel binding pathways. Moreover, the
presented study can be used, for instance, for informing multi-
scale kinetic models of cardiovascular (and other) drug effects
on cellular, tissue and organ levels (Clancy et al., 2016), as
was done in our recent study, where we modeled charged and
neutral flecainide (cardiac sodium channel blocker with some
pro-arrhythmic proclivity) effects (Yang et al., 2016). We are
planning a similar extension of the current study along with
atomistic structure based investigations of sotalol interactions
with hERG using a combination of molecular docking and all-
atom molecular dynamics simulations. Several other drugs with
different hERG affinities and pro-arrhythmia proclivities will be
investigated as well for both lipid membrane and hERG binding
assays.
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